Literature DB >> 19110304

Vitamin A metabolism is impaired in human ovarian cancer.

Stephen J Williams1, Dusica Cvetkovic, Thomas C Hamilton.   

Abstract

OBJECTIVES: We have previously reported that loss in expression of a protein considered critical for vitamin A homeostasis, cellular retinol-binding protein 1 (CRBP1), is an early event in ovarian carcinogenesis. The aim of the present study was to determine if loss of vitamin A metabolism also occurs early in ovarian oncogenesis.
METHODS: We assessed CRBP1 expression by immunohistochemistry in ovaries prophylactically removed from women with a genetic risk for ovarian cancer. Furthermore, we investigated the ability of normal, immortalized but nontumorigenic, and tumorigenic human ovarian epithelial cells to synthesize retinoic acid and retinaldehyde when challenged with a physiological dose of retinol, and determined expression levels of the retinoid-related genes, RARalpha, RXRalpha, CRABP1, CRABP2, RALDH1 and RALDH2 in these cells.
RESULTS: Immunohistochemistry revealed loss of CRBP1 expression in potentially preneoplastic lesions in prophylactic oophorectomies. HPLC analysis of vitamin A metabolism showed production of retinoic acid in four independent, normal human ovarian surface epithelial (HOSE) cell cultures upon exposure to retinol. However, only one of two SV40-immortalized HOSE cell lines made RA, while none of the ovarian carcinoma cell lines produced detectable RA due to complete loss of RALDH2.
CONCLUSIONS: The impaired conversion of retinol to RA in ovarian cancer cells and decreased CRBP1 protein expression in prophylactic oophorectomies support our hypothesis that concomitant losses of vitamin A metabolism and CRBP1 expression contribute to ovarian oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19110304      PMCID: PMC2737361          DOI: 10.1016/j.ygyno.2008.11.015

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  58 in total

1.  Carotenoids, antioxidants and ovarian cancer risk in pre- and postmenopausal women.

Authors:  D W Cramer; H Kuper; B L Harlow; L Titus-Ernstoff
Journal:  Int J Cancer       Date:  2001-10-01       Impact factor: 7.396

2.  Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer.

Authors:  A K Godwin; J R Testa; L M Handel; Z Liu; L A Vanderveer; P A Tracey; T C Hamilton
Journal:  J Natl Cancer Inst       Date:  1992-04-15       Impact factor: 13.506

3.  Alterations in cellular retinol metabolism contribute to differential retinoid responsiveness in normal human mammary epithelial cells versus breast cancer cells.

Authors:  Leslie J Hayden; Michael A Satre
Journal:  Breast Cancer Res Treat       Date:  2002-03       Impact factor: 4.872

4.  Retinoic acid biosynthesis by normal human breast epithelium is via aldehyde dehydrogenase 6, absent in MCF-7 cells.

Authors:  B N Rexer; W L Zheng; D E Ong
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

5.  Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line.

Authors:  William F Holmes; Dianne Robert Soprano; Kenneth J Soprano
Journal:  J Biol Chem       Date:  2002-09-16       Impact factor: 5.157

6.  Prophylactic oophorectomy: a morphologic and immunohistochemical study.

Authors:  Peter W Schlosshauer; Carmel J Cohen; Frederique Penault-Llorca; Carlos R Miranda; Yves-Jean Bignon; Jacques Dauplat; Liane Deligdisch
Journal:  Cancer       Date:  2003-12-15       Impact factor: 6.860

7.  Cellular retinol-binding protein-1 in hepatocellular carcinoma correlates with beta-catenin, Ki-67 index, and patient survival.

Authors:  Annette Schmitt-Gräff; Viktoria Ertelt; Hans-P Allgaier; Konrad Koelble; Manfred Olschewski; Roland Nitschke; Marie-L Bochaton-Piallat; Giulio Gabbiani; Hubert E Blum
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

8.  Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma.

Authors:  Keishi Yamashita; Sunil Upadhyay; Motonobu Osada; Mohammad O Hoque; Yan Xiao; Masaki Mori; Fumiaki Sato; Stephen J Meltzer; David Sidransky
Journal:  Cancer Cell       Date:  2002-12       Impact factor: 31.743

9.  Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer.

Authors:  C Jerónimo; R Henrique; J Oliveira; F Lobo; I Pais; M R Teixeira; C Lopes
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

10.  Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer.

Authors:  Dusica Cvetković; Stephen J Williams; Thomas C Hamilton
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

View more
  9 in total

1.  Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas.

Authors:  Benito Campos; Franz-Simon Centner; Justo Lorenzo Bermejo; Ramadan Ali; Katharina Dorsch; Feng Wan; Jörg Felsberg; Rezvan Ahmadi; Niels Grabe; Guido Reifenberger; Andreas Unterberg; Jürgen Burhenne; Christel Herold-Mende
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk.

Authors:  Ellen L Goode; Kristin L White; Robert A Vierkant; Catherine M Phelan; Julie M Cunningham; Joellen M Schildkraut; Andrew Berchuck; Melissa C Larson; Brooke L Fridley; Janet E Olson; Penelope M Webb; Xiaoqing Chen; Jonathan Beesley; Georgia Chenevix-Trench; Thomas A Sellers
Journal:  Mol Carcinog       Date:  2010-12-28       Impact factor: 4.784

3.  CRABP1-reduced expression is associated with poorer prognosis in serous and clear cell ovarian adenocarcinoma.

Authors:  Takahito Miyake; Yutaka Ueda; Shinya Matsuzaki; Takashi Miyatake; Kiyoshi Yoshino; Masami Fujita; Taisei Nomura; Takayuki Enomoto; Tadashi Kimura
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-23       Impact factor: 4.553

Review 4.  Cellular retinoid binding-proteins, CRBP, CRABP, FABP5: Effects on retinoid metabolism, function and related diseases.

Authors:  Joseph L Napoli
Journal:  Pharmacol Ther       Date:  2017-01-27       Impact factor: 12.310

5.  Association between cytoplasmic CRABP2, altered retinoic acid signaling, and poor prognosis in glioblastoma.

Authors:  Rong-Zong Liu; Shuai Li; Elizabeth Garcia; Darryl D Glubrecht; Ho Yin Poon; Jacob C Easaw; Roseline Godbout
Journal:  Glia       Date:  2016-02-19       Impact factor: 7.452

6.  Altered expression of multiple genes involved in retinoic acid biosynthesis in human colorectal cancer.

Authors:  Ekaterina S Kropotova; Olga L Zinovieva; Alisa F Zyryanova; Vera I Dybovaya; Vladimir S Prasolov; Sergey F Beresten; Nina Yu Oparina; Tamara D Mashkova
Journal:  Pathol Oncol Res       Date:  2014-03-06       Impact factor: 3.201

7.  HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas.

Authors:  Efterpi Kostareli; Dana Holzinger; Olga Bogatyrova; Thomas Hielscher; Gunnar Wichmann; Michaela Keck; Bernd Lahrmann; Niels Grabe; Christa Flechtenmacher; Christopher R Schmidt; Tanguy Seiwert; Gerhard Dyckhoff; Andreas Dietz; Daniela Höfler; Michael Pawlita; Axel Benner; Franz X Bosch; Peter Plinkert; Christoph Plass; Dieter Weichenhan; Jochen Hess
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

8.  Downregulation of DHRS9 expression in colorectal cancer tissues and its prognostic significance.

Authors:  Liang Hu; Hai-Yang Chen; Tao Han; Guang-Zhen Yang; Dan Feng; Chen-Ye Qi; Hui Gong; Yan-Xia Zhai; Qing-Ping Cai; Chun-Fang Gao
Journal:  Tumour Biol       Date:  2015-08-08

9.  Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progression.

Authors:  R Gupta; Q Yang; S K Dogra; N Wajapeyee
Journal:  Oncogene       Date:  2017-03-13       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.